Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Jan;105(1):77–82. doi: 10.1111/j.1476-5381.1992.tb14213.x

Role of muscarinic receptor subtypes in central antinociception.

A Bartolini 1, C Ghelardini 1, L Fantetti 1, M Malcangio 1, P Malmberg-Aiello 1, A Giotti 1
PMCID: PMC1908635  PMID: 1375858

Abstract

1. The ability to modify the pain threshold by the two M1-muscarinic agonists: McN-A-343 and AF-102B and by the specific M2-agonist arecaidine was examined in mice and rats by using three different noxious stimuli: chemical (writhing test), thermic (hot-plate test) and mechanical (paw pressure test). 2. In the mouse hot-plate test McN-A-343 (20-50 micrograms per mouse i.c.v.) and AF-102B (1-10 mg kg-1 i.p.) produced significant antinociception which was prevented by atropine (1 microgram per mouse i.c.v.) and by the two selective M1 antagonists: pirenzepine (0.01 micrograms per mouse i.c.v.) and dicyclomine (0.08 micrograms per mouse i.c.v. or 10 mg kg-1 i.p.) but not by the specific M2-antagonist AFDX-116 (0.1 micrograms per mouse i.c.v.), naloxone (1 mg kg-1 i.p.) or by the acetylcholine (ACh) depletor hemicholinium-3 (HC-3) (1 micrograms per mouse i.c.v.). McN-A-343 and AF-102B were able to increase the pain threshold also in the mouse acetic acid writhing test and in rat paw pressure test. These antinociceptive effects were completely prevented by dicyclomine (0.08 micrograms per mouse i.c.v. or 10 mg kg-1 i.p.) but not by AFDX-116 (0.1 microgram per mouse or rat i.c.v.). 3. In contrast with the M1-agonists, the M2-agonist arecaidine (0.1-2 micrograms per mouse or rat i.c.v.) did not induce antinociception in all three analgesic tests. However, arecaidine, at the same i.c.v. doses, was able to reduce the pain threshold in the hot-plate and paw pressure tests.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlow R. B., Weston-Smith P. The relative potencies of some agonists at M2 muscarinic receptors in guinea-pig ileum, atria and bronchi. Br J Pharmacol. 1985 Jun;85(2):437–440. doi: 10.1111/j.1476-5381.1985.tb08879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartolini A., Galli A., Ghelardini C., Giotti A., Malcangio M., Malmberg-Aiello P., Zucchi P. L. Antinociception induced by systemic administration of local anaesthetics depends on a central cholinergic mechanism. Br J Pharmacol. 1987 Dec;92(4):711–721. doi: 10.1111/j.1476-5381.1987.tb11375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chernov H. I., Wilson D. E., Fowler W. F., Plummer A. J. Non-specificity of the mouse writhing test. Arch Int Pharmacodyn Ther. 1967 May;167(1):171–178. [PubMed] [Google Scholar]
  4. Fisher A., Brandeis R., Pittel Z., Karton I., Sapir M., Dachir S., Levy A., Heldman E. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci Lett. 1989 Jul 31;102(2-3):325–331. doi: 10.1016/0304-3940(89)90100-6. [DOI] [PubMed] [Google Scholar]
  5. GEORGE R., HASLETT W. L., JENDEN D. J. The central action of a metabolite of tremorine. Life Sci. 1962 Aug;1:361–363. doi: 10.1016/0024-3205(62)90060-7. [DOI] [PubMed] [Google Scholar]
  6. Ghelardini C., Malmberg-Aiello P., Giotti A., Malcangio M., Bartolini A. Investigation into atropine-induced antinociception. Br J Pharmacol. 1990 Sep;101(1):49–54. doi: 10.1111/j.1476-5381.1990.tb12087.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Giachetti A., Micheletti R., Montagna E. Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist. Life Sci. 1986 May 5;38(18):1663–1672. doi: 10.1016/0024-3205(86)90410-8. [DOI] [PubMed] [Google Scholar]
  8. Giraldo E., Martos F., Gomez A., Garcia A., Vigano M. A., Ladinsky H., Sanchez de La Cuesta F. Characterization of muscarinic receptor subtypes in human tissues. Life Sci. 1988;43(19):1507–1515. doi: 10.1016/0024-3205(88)90398-0. [DOI] [PubMed] [Google Scholar]
  9. HALEY T. J., MCCORMICK W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother. 1957 Mar;12(1):12–15. doi: 10.1111/j.1476-5381.1957.tb01354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. HENDERSHOT L. C., FORSAITH J. Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther. 1959 Mar;125(3):237–240. [PubMed] [Google Scholar]
  11. HERZ A. [The effects of arecoline on the central nervous system]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1962;242:414–429. [PubMed] [Google Scholar]
  12. Hammer R., Berrie C. P., Birdsall N. J., Burgen A. S., Hulme E. C. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980 Jan 3;283(5742):90–92. doi: 10.1038/283090a0. [DOI] [PubMed] [Google Scholar]
  13. Hammer R., Giachetti A. Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 1982 Dec 27;31(26):2991–2998. doi: 10.1016/0024-3205(82)90066-2. [DOI] [PubMed] [Google Scholar]
  14. Harris L. S., Dewey W. L., Howes J. F., Kennedy J. S., Pars H. Narcotic-antagonist analgesics: interactions with cholinergic systems. J Pharmacol Exp Ther. 1969 Sep;169(1):17–22. [PubMed] [Google Scholar]
  15. Ireson J. D. A comparison of the antinociceptive actions of cholinomimetic and morphine-like drugs. Br J Pharmacol. 1970 Sep;40(1):92–101. doi: 10.1111/j.1476-5381.1970.tb10614.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Iwamoto E. T. Antinociception after nicotine administration into the mesopontine tegmentum of rats: evidence for muscarinic actions. J Pharmacol Exp Ther. 1989 Nov;251(2):412–421. [PubMed] [Google Scholar]
  17. LENKE D. Narkosepotenzierende und analgetische Wirkung von 1,4-Dipyrrolidino-2-butin. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1958;234(1):35–45. [PubMed] [Google Scholar]
  18. Lambrecht G., Moser U., Mutschler E., Walther G., Wess J. Muscarinic ganglionic stimulants: conformationally restrained analogues related to [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride. J Med Chem. 1986 Jul;29(7):1309–1311. doi: 10.1021/jm00157a036. [DOI] [PubMed] [Google Scholar]
  19. Mash D. C., Flynn D. D., Potter L. T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 1985 May 31;228(4703):1115–1117. doi: 10.1126/science.3992249. [DOI] [PubMed] [Google Scholar]
  20. Mash D. C., Potter L. T. Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience. 1986 Oct;19(2):551–564. doi: 10.1016/0306-4522(86)90280-0. [DOI] [PubMed] [Google Scholar]
  21. Mutschler E., Hultzsch K. Uber Struktur-Wirkungs-Beziehungen von ungesättigten Estern des Arecaidins und Dihydroarecaidins. Arzneimittelforschung. 1973 May;23(5):732–737. [PubMed] [Google Scholar]
  22. Nakahara N., Fujise N., Kawanishi G., Mizobe F. Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia. Brain Res. 1990 Jan 15;507(1):172–175. doi: 10.1016/0006-8993(90)90541-i. [DOI] [PubMed] [Google Scholar]
  23. Nilvebrant L., Sparf B. Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol. 1986 Apr 9;123(1):133–143. doi: 10.1016/0014-2999(86)90697-7. [DOI] [PubMed] [Google Scholar]
  24. Ono S., Saito Y., Ohgane N., Kawanishi G., Mizobe F. Heterogeneity of muscarinic autoreceptors and heteroreceptors in the rat brain: effects of a novel M1 agonist, AF102B. Eur J Pharmacol. 1988 Oct 11;155(1-2):77–84. doi: 10.1016/0014-2999(88)90404-9. [DOI] [PubMed] [Google Scholar]
  25. Pedigo N. W., Dewey W. L., Harris L. S. Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J Pharmacol Exp Ther. 1975 Jun;193(3):845–852. [PubMed] [Google Scholar]
  26. Pohorecki R., Head R., Domino E. F. Effects of selected muscarinic cholinergic antagonists on [3H]acetylcholine release from rat hippocampal slices. J Pharmacol Exp Ther. 1988 Jan;244(1):213–217. [PubMed] [Google Scholar]
  27. Raiteri M., Leardi R., Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther. 1984 Jan;228(1):209–214. [PubMed] [Google Scholar]
  28. Spencer D. G., Jr, Horváth E., Traber J. Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections. Brain Res. 1986 Aug 13;380(1):59–68. doi: 10.1016/0006-8993(86)91429-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES